Raising awareness on senolytic drugs as a promising anti-ageing medicine
Longevity Technology - 30-Apr-2021Senolytic Therapy Network aims to take the senotherapeutics from lab to clinic
Join the club for FREE to access the whole archive and other member benefits.
Company developing the world’s first Certified Senotherapeutics Practictioner program.
The Senolytic Therapy Network was founded to serve as the premier organization for studying and implementing senolytic therapies into clinical practice. We firmly believe that successful senolytic therapies are the necessary next step in advancing the fight against aging and promoting successful organ and tissue regeneration.
Board members of Senolytic Therapy Network are Dr Vincent Giampapa, Jin-Xiong She, Dr Edwin Lee and Luis Martinez.
Dr. Vincent Giampapa is Board Certified in Plastic and Reconstructive Surgery and Anti-Aging Medicine, and the Founding Director of Plastic Surgery Center International, The Giampapa Institute for Anti-Aging Medical Therapy, and the Regenerative Medicine Institute (RMI), located in Costa Rica. Dr. Giampapa believes RMI will become the global portal for stem cell therapy and advanced regenerative medicine research within the biotechnology incubator park (also slated to be a major component of RMI). Dr. Giampapa was nominated in 2014 for a Nobel Prize for his groundbreaking research into cellular restoration technology. He is a co-founder of The Academy of Anti-Aging Medicine (A4M), comprised of over 26,000 members representing over 110 nations, the first president of the Board of Anti-Aging Medicine and the founder of Healthycell, an advanced cell health nutritional supplement and Stem Bank, a blood-derived stem cell extraction and Storage Company.
Jin-Xiong She, Ph.D. is a Professor and Eminent Scholar and founding director of the Center for Biotechnology and Genomic Medicine at the Medical College of Georgia (MCG), Augusta University. Dr. She has almost four decades of academic research experience and published over 300 peer-reviewed scientific papers. His research focuses on the development and application of high throughput omic and bioinformatic technologies for biomarker discovery and design of novel prevention and intervention strategies for human diseases and extension of healthspan. Dr. She has extensive experience in designing and managing large-scale, longitudinal, and population-based studies.
Visit website: https://senolytictherapynetwork.com/
Details last updated 01-May-2021
Founder and CEO, Jinfiniti Precision Medicine and Director of the MCG Center for Biotechnology and Genomic Medicine,
Senolytic Therapy Network aims to take the senotherapeutics from lab to clinic